
SCR revolutionizes banking industry with a hybrid biobanking model, offering diverse, FDA-approved stem cell storage and regenerative solutions in Houston.
Stem Cell Reserve, founded by Raymond Mouzannar, PhD, is dedicated to revolutionizing the banking industry through its innovative hybrid biobanking model. The company offers a range of FDA-approved stem cell storage and regenerative solutions, focusing on both private and public banking products. Utilizing proprietary techniques, Stem Cell Reserve extracts all stem cells and a supportive bioscaffold from umbilical cord tissue, aiming to develop superior regenerative therapies. Their mission is to harness the power of the umbilical cord to improve lives globally.
Notable figures affiliated with Stem Cell Reserve include its founder, Raymond Mouzannar, a seasoned stem cell scientist and epigeneticist. The company has achieved significant milestones in the field of regenerative medicine by introducing new stem cell products that challenge traditional cord blood banking models. With its pioneering approach and adherence to stringent regulatory standards, Stem Cell Reserve has made a substantial impact on the industry, positioning itself as a leader in advancing stem cell science and improving patient outcomes.

StemSave
stemsave.com

Celltex Therapeutics
celltexbank.com

Personalized Stem Cells

Stemcyte
stemcyte.com

American CryoStem

U.S. Stem Cell
us-stemcell.com

StemBioSys
stembiosys.com

Stemgenics
stemgenics.com

Next Healthcare

AdiCyte

MyCordBank.com
mycordbank.com

Stemedica Cell Technologies
stemedica.com

MitoStem

LaCell

Ossium Health
ossiumhealth.com
Companies similar to Stem Cell Reserve include StemSave, Celltex Therapeutics, Personalized Stem Cells and Stemcyte.
Stem Cell Reserve was founded in 2009.
Stem Cell Reserve's headquarters is located in Houston, TX, US.
Stem Cell Reserve's most recent funding round was for $2M (USD) in May 2017.
As of May 2, 2017, Stem Cell Reserve has raised a total of $2M (USD).
Stem Cell Reserve has 30 employees as of Feb 4, 2024.